Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy

Anticancer vaccination is a promising approach to increase the efficacy of cytotoxic T lymphocyte–associated protein 4 (CTLA-4) and programmed death ligand 1 (PD-L1) checkpoint blockade therapies. However, the landmark FDA registration trial for anti–CTLA-4 therapy (ipilimumab) revealed a complete l...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Clin Invest
Hoofdauteurs: Hailemichael, Yared, Woods, Amber, Fu, Tihui, He, Qiuming, Nielsen, Michael C., Hasan, Farah, Roszik, Jason, Xiao, Zhilan, Vianden, Christina, Khong, Hiep, Singh, Manisha, Sharma, Meenu, Faak, Faisal, Moore, Derek, Dai, Zhimin, Anthony, Scott M., Schluns, Kimberly S., Sharma, Padmanee, Engelhard, Victor H., Overwijk, Willem W.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society for Clinical Investigation 2018
Onderwerpen:
Research Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5873868/
https://ncbi.nlm.nih.gov/pubmed/29480817
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI93303
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items